Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Molecular Diagnosis & Therapy
Published in: Molecular Diagnosis & Therapy 5/2007

01-09-2007 | Short Communication

Modeling the Impact of Genetic Screening Technologies on Healthcare

Theoretical Model for Asthma in Children

Authors: Dr Emma Gutiérrez de Mesa, Ignacio Hidalgo, Panayotis Christidis, Juan Carlos Ciscar, Eva Vegas, Dolores Ibarreta

Published in: Molecular Diagnosis & Therapy | Issue 5/2007

Login to get access

Abstract

Background and objective: This study focuses on the potential impact of genetic screening technologies on healthcare. Genetic screening for asthma in children was chosen as a case study to explore the cost effectiveness of applying early genetic screening to infants, and preventive treatment to the population at risk. Early intervention could prevent progression and facilitate clinical management of the disease. From the elite group of genetic markers that have been associated with asthma-related phenotypes, ADAM33 was the first published candidate gene detected by a positional cloning approach, marking the entry of asthma research into the genomic era. The model was, therefore, initially set for an ex ante analysis of the cost effectiveness of applying the preventive program to an infant population at risk, i.e. infants presenting wheezing episodes during the first year of life, and the ADAM33 ST+7 genetic marker, with the idea of expanding to further markers and their combinations lat a later date.
Methods: In accordance with the US National Heart, Lung, and Blood Institute, four categories of asthma were considered. A Markov model was constructed, consisting of six mutually exclusive disease states (including healthy and dead states) with a simulation horizon of 100 years and a cycle length of 1 year.
We define a scenario where early genetic screening was applied to infants presenting wheezing episodes during the first year of life and a preventive treatment to those children within this group who tested positive for selected ADAM33 polymorphism (ST+7). The cost-effectiveness analysis was performed from the third-party payer and patient perspective after year 6. We applied our model to a hypothetical cohort of 100 European infants.
Results: The number of quality-adjusted life-years (QALYs) gained during the 6 years was 1.483, and the incremental cost-effectiveness ratio per QALY gained was €10 100/QALY. A sensitivity analysis was carried out that varied the discount rate and cost of genetic testing, and considered two different transition matrices for the preventive program. Three main conclusions were drawn from the sensitivity analysis. Firstly, if the discount rate for both cost and health outcomes is increased by 2%, the cost effectiveness of the preventive program does not vary significantly. Discounting costs and benefits at 5%, the preventive program appears cost effective (€11 100/QALY). Secondly, if the cost of genetic testing is increased to €100, the cost effectiveness of the preventive program remains within the limits of cost effectiveness. Thirdly, the cost of genetic screening, together with transition probabilities between health states, will determine the cost effectiveness of applying a preventive program based on genetic information.
Conclusions: Preventive treatment based on an early genetic screening of those children who present wheezing episodes during the first year of life, with treatment applied to those who test positive for the asthma-associated genetic marker ADAM33 ST+7, is theoretically cost effective. The model is a valuable tool for the ex ante assessment of the cost effectiveness of preventive schemes based on genetic screening. The value of modeling prior to clinical trials lies in informing study design and setting priorities for future research.
Literature
1.
Arenas-Guzman R, Tosti A, Hay R, et al. Pharmacoeconomics: an aid to better decision-making. J Eur Acad Dermatol Venereol 2005; 19Suppl. 1: 34–9PubMedCrossRef
2.
Collins FS, Green ED, Guttmacher AE, et al. A vision for the future of genomics research. Nature, 2003; 422(6934): 835–47PubMedCrossRef
3.
4.
European Respiratory Society. European lung white book. Lausanne: European Respiratory Society Publication Department, 2003
5.
European Commission. The social situation in the European Union in 2003. Luxembourg: European Commission Publications, 2004
6.
van den Akker-van Marie ME, Bruil J, Detmar SB. Evaluation of cost of disease: assessing the burden to society of asthma in children in the European Union [report 21]. Delft: TOO, 2004
7.
The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema. Lancet 1998; 351: 1225–32CrossRef
8.
European Community Respiratory Health Survey (ECRHS). Variations in the prevalence of respiratory symptoms, self reported asthma attacks, and use of asthma medication in the European Community. Respiratory Health Survey. Eur Respir J 1996; 9: 687–95CrossRef
9.
Aubier M, Neukirch F, Annesi-Maesano I. Epidemiology of asthma and allergies: the prevalence of allergies increases worldwide, and asthma has reached his highest-ever prevalence in Europe: why? Bull Acad Natl Med 2005; 189(7): 1419–34; discussion 1434PubMed
10.
NIH. Global strategy for asthma management and prevention. Bethesda (MD): National Heart, Lung, and Blood Institute, 2002: 176
11.
12.
European Environment Agency and the Joint Research Centre (JRC) of the European Commission. Environment and health. EEA Report No 10/2005. Luxembourg: European Commission Publications, 2005
13.
Sennhauser FH, Braun-Fahrlander C, Wildhaber JH. The burden of asthma in children: a European perspective. Paediatr Respir Rev 2005; 6(1): 2–7PubMedCrossRef
14.
15.
King ME, Mannino DM, Holguin F. Risk factors for asthma incidence: a review of recent prospective evidence. Panminerva Med 2004; 46(2): 97–110PubMed
16.
Melen E, Wickman M, Nordvall SL, et al. Influence of early and current environmental exposure factors on sensitization and outcome of asthma in pre-school children. Allergy 2001; 56(7): 646–52PubMedCrossRef
17.
Brussee JE, Smit HA, van Strien RT, et al. Allergen exposure in infancy and the development of sensitization, wheeze, and asthma at 4 years. J Allergy Clin Immunol 2005; 115(5): 946–52PubMedCrossRef
18.
Lewis TC, Robins TG, Dvonch JT, et al. Air pollution-associated changes in lung function among asthmatic children in Detroit. Environ Health Perspect 2005; 113(8): 1068–75PubMedCrossRef
19.
Willers SM, Brunekreef B, Oldenwening M, et al. Gas cooking, kitchen ventilation, and asthma, allergic symptoms and sensitization in young children: the PIAMA study. Allergy 2006; 61(5): 563–8PubMedCrossRef
20.
21.
Holgate ST, Yang Y, Haitchi HM, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc 2006; 3(5): 440–3PubMedCrossRef
22.
Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun 2006; 7(2): 95–100PubMedCrossRef
23.
Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332(3): 133–8PubMedCrossRef
24.
Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol 2001; 108(5): 720–5PubMedCrossRef
25.
Holgate ST. A need for circulating biomarkers of severe persistent asthma and its treatment. Clin Exp Allergy 2006; 36(11): 1355–6PubMedCrossRef
26.
Jongepier H, Boezen HM, Dijkastra A, et al. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy 2004; 34(5): 757–60PubMedCrossRef
27.
Noguchi E, Ohtsuki Y, Tokunaga K, et al. ADAM33 polymorphisms are associated with asthma susceptibility in a Japanese population. Clin Exp Allergy 2006; 36(5): 602–8PubMedCrossRef
28.
Kedda MA, Duffy DL, Bradley B, et al. ADAM33 haplotypes are associated with asthma in a large Australian population. Eur J Hum Genet 2006; 14(9): 1027–36PubMedCrossRef
29.
van Diemen CC, Postma DS, Vonk JM, et al. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med 2005; 172(3): 329–33PubMedCrossRef
30.
Simpson A, Maniatis N, Jury F, et al. Polymorphisms in a disintegrin and metalloprotease 33 (ADAM33) predict impaired early-life lung function. Am J Respir Crit Care Med 2005; 172(1): 55–60PubMedCrossRef
31.
Liu AH. Consider the child: how early should we treat? J Allergy Clin Immunol 2004; 113(1 Suppl.): S19–24PubMedCrossRef
32.
Larsen GL, Kang JK, Guilbert T, et al. Assessing respiratory function in young children: developmental considerations. J Allergy Clin Immunol 2005; 115(4): 657–66PubMedCrossRef
33.
Van Eerdewegh P, Little RD, Duguis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418(6896): 426–30PubMedCrossRef
34.
Hirota T, Hasegawa K, Obara K, et al. Association between ADAM33 polymorphisms and adult asthma in the Japanese population. Clin Exp Allergy 2006; 36(7): 884–91PubMedCrossRef
35.
Howard TD, Postma DS, Jongepier H, et al. Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations. J Allergy Clin Immunol 2003; 112(4): 717–22PubMedCrossRef
36.
Lee JH, Park HS, Park SW, et al. ADAM33 polymorphism: association with bronchial hyper-responsiveness in Korean asthmatics. Clin Exp Allergy 2004; 34(6): 860–5PubMedCrossRef
37.
Werner M, Herbon N, Gohlke H, et al. Asthma is associated with single-nucleotide polymorphisms in ADAM33. Clin Exp Allergy 2004; 34(1): 26–31PubMedCrossRef
38.
Raby BA, Silverman EK, Kwiatkowski AS, et al. ADAM33 polymorphisms and phenotype associations in childhood asthma. J Allergy Clin Immunol 2004; 113(6): 1071–8PubMedCrossRef
39.
Schedel M, Depner M, Schoen C, et al. The role of polymorphisms in ADAM33, a disintegrin and metalloprotease 33, in childhood asthma and lung function in two German populations. Respir Res 2006; 7: 91PubMedCrossRef
40.
Wang P, Liu QJ, Li JS, et al. Lack of association between ADAM33 gene and asthma in a Chinese population. Int J Immunogenet 2006; 33(4): 303–6PubMedCrossRef
41.
Blakey J, Halapi E, Bjornsdottir US, et al. Contribution of ADAM33 polimorphisms to the population risk of asthma. Thorax 2005; 60(4): 274–6PubMedCrossRef
42.
Munakata M, Harada Y, Ishida T, et al. Molecular-based haplotype analysis of the beta 2-adrenergic receptor gene (ADRB2) in Japanese asthmatic and non-asthmatic subjects. Allergol Int 2006; 55(2): 191–8PubMedCrossRef
43.
Janssens AC, Aulchenko YS, Elefante S, et al. Predictive testing for complex diseases using multiple genes: fact or fiction? Genet Med 2006; 8(7): 395–400PubMedCrossRef
44.
Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20(3): 183–94PubMedCrossRef
45.
Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13(4): 397–409PubMedCrossRef
46.
47.
Salomon JA, Weinstein MC, Goldie SJ. Taking account of future technology in cost effectiveness analysis. BMJ 2004; 329(7468): 733–6PubMedCrossRef
48.
Dong H, Buxton M. Early assessment of the likely cost-effectiveness of a new technology: a Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. Int J Technol Assess Health Care 2006; 22(2): 191–202PubMedCrossRef
49.
Combescure C, Chanez P, Saint Pierre P, et al. Assessment of variations in control of asthma over time. Eur Respir J 2003; 22(2): 298–304PubMedCrossRef
50.
Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004; 7(1): 43–9PubMedCrossRef
51.
Cooper NJ, Sutton AJ, Abrams KR, et al. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ 2004; 13(3): 203–26PubMedCrossRef
52.
Buxton MJ. How much are health-care systems prepared to pay to produce a QALY? Eur J Health Econ 2005; 6(4): 285–7PubMedCrossRef
53.
Coughlin MT, Angus DC. Economic evaluation of new therapies in critical illness. Crit Care Med 2003; 31(1 Suppl.): S7–16PubMedCrossRef
54.
Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
55.
Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
56.
57.
Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19(1): 61–7PubMedCrossRef
58.
Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111(6): 1212–8PubMedCrossRef
59.
Schramm B, Ehlken B, Smala A, et al. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 2003; 21(1): 116–22PubMedCrossRef
60.
Lasserson T, Cates CK, Jones AB, et al. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; (2): CD005309
61.
Zika E, Gurwitz D, Ibarreta D. Pharmacogenetics and pharmacogenomics: state of the art and potential socio-economic impacts in the EU. EU Report. Luxembourg: European Commission, 2006
62.
Priest VG, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomic 2006; 24(8): 767–81CrossRef
63.
Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 2004; 43(2): 1156–63
64.
Marra CA, Esdaile JM, Anis AH, et al. Practical pharmacogenetics: the cost-effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29(12): 2507–12PubMed
65.
Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltrans-ferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 25(9): 1069–77CrossRef
66.
Chen S. The cytochrome P4502D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60(5): 522–34PubMedCrossRef
67.
Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002; 315: 137–55PubMedCrossRef
68.
Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116(5): 325–31PubMedCrossRef
69.
Sullivan SD, Buxton M, Andersson LF, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003; 112(6): 1229–36PubMedCrossRef
70.
Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23(6): 619–37PubMedCrossRef
71.
Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005; 23(7): 639–49PubMedCrossRef
72.
Nootheti S, Bielory L. Risk of cataracts and glaucoma with inhaled steroid use in children. Compr Ophthalmol Update 2006; 7(1): 31–9PubMed
73.
Bell CM, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332(7543): 699–703PubMedCrossRef
74.
Brennan A, Akehurst R. Modelling in health economic evaluation: what is its place? What is its value? Pharmacoeconomics 2000; 17(5): 445–59PubMedCrossRef
75.
Gold BD. Asthma and gastroesophageal reflux disease in children: exploring the relationship. J Pediatr 2005; 146 (3 Suppl. 1): S13–20PubMedCrossRef
76.
Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case. J Am Acad Dematol 2000; 42(4): 628–32
77.
Janssens AC, van Duijn CM. Towards predictive genetic testing of complex diseases. Eur J Epidemiol 2006; 21(12): 869–70PubMedCrossRef
Metadata
Title
Modeling the Impact of Genetic Screening Technologies on Healthcare
Theoretical Model for Asthma in Children
Authors
Dr Emma Gutiérrez de Mesa
Ignacio Hidalgo
Panayotis Christidis
Juan Carlos Ciscar
Eva Vegas
Dolores Ibarreta
Publication date
01-09-2007
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 5/2007
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/BF03256252

Other articles of this Issue 5/2007

Molecular Diagnosis & Therapy 5/2007 Go to the issue

Original Research Article

Quantitation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Using Locked Nucleic Acid-Modified, Fluorescently Labeled Hybridization Probes and Real-Time PCR Technology

Genetic Disorders

Laboratory Diagnosis of Congenital Disorders of Glycosylation Type I by Analysis of Transferrin Glycoforms

Correspondence

Rapid Detection of the DPYD IVS14+1G>A Mutation for Screening Patients to Prevent Fluorouracil-Related Toxicity

News

From the World Literature

Correspondence

Author’s Reply

Cancer

Gene Discovery in Cervical Cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits